Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis

Leonille Schweizer1,2 | Wolfgang Hartmann3 | Arend Koch1,2 |
Maximilian Nunninger4 | Ulrich-Wilhelm Thomale5 | Valentina Pennacchietti5 |
Anna Tietze4 | Denise Horn6 | Kristian W. Pajtler7,8,9 | Steffen Hirsch8,9,10 |
Ilse Wieland11 | Hedwig Deubzer12,13 | Rainer Rossi14 | Pablo Hernáiz Driever12 |
Katja von Hoff12 | Barbara von Zezschwitz12

DICER1 mutant CNS sarcoma is a newly defined entity that may present with various morphologies and is characterised by a distinct DNA methylation profile [1–3]. Tumours occur sporadically or in the context of DICER1 syndrome as well as rarely in neurofibromatosis type 1 [1, 4]. Most tumours present with additional mutations in TP53 and RAS-pathway genes [1, 4–6]. Although the mutational landscape of DICER1 mutant CNS sarcomas has been investigated, not much is known about the cellular origin of this entity. We present a male...
neonate with severe muscular hypotonia and multiple melanocytic naevi. The prenatal period was uneventful except for a large arachnoid cyst with cerebellar hypoplasia. At the age of 6 weeks, he developed paraplegia of the lower limbs. A magnetic resonance imaging showed brain melanosis (Figure 1A) and a thoracic intraspinal and paraspinal tumour (Figure S1, online resource). The tumour extended through the intravertebral foramen and was focally abutting the pleura (see Figure S1C), but did not extend into the pleural cavity. Intrapulmonary or distant lesions were not identified.

The tumour was incompletely resected and demonstrated variable degree of maturation. Low-grade mesenchymal areas with scattered lipomatous cell nests and numerous pseudo-mesnierian corpuscles (PMCs) predominated over undifferentiated and sarcomatous, MPNST-like areas (approximately 70% vs 30% of tumour tissue; Figures 1A and S2, online resource). The immunohistochemical expression pattern was heterogeneous: PMCs strongly expressed WT1, SOX10 and CD56. The sarcomatous component demonstrated focal reactivity for SOX10 as well as several dispersed WT1 and p75 positive and single SOX10 and MITF positive tumour cells. CD56 was strongly expressed by the sarcomatous component, but negative in undifferentiated tumour areas. Nuclear p53 accumulation was mainly seen in the sarcomatous and primitive areas, but was absent in low-grade areas. The tumour cells did not express desmin, SMA, MyoD1, TLE-1, MAP2, synaptophysin or chromogranin A. The proliferation activity was very high in undifferentiated areas (Ki67 90%), markedly increased in sarcomatous areas (15–25%) and low in mesenchymal areas with PMCs (2%) (Figure S2, online resource).

Primitive and sarcomatous areas of the tumour were both classified as primary intracranial sarcoma, DICER1-mutant based on DNA methylation profiling (brain tumour classifier v12.5: classifier score 0.99; www.molecularneuropathology.org, [7]). The sarcomatous tumour component showed a flat copy number profile, whereas the primitive tumour component demonstrated partial gain of chromosome 9 and partial loss of chromosome 11 (Figure S3, online resource). Next-generation sequencing (NGS) demonstrated a constitutional pathogenic variant (c.3007C > T p.(Arg1003*)) (RefSeq Transcript NM_030621.4) inherited from the father with biallelic inactivation of DICER1 by a second pathogenic DICER1 c.5439G > T p.(Glu1813Asp) hotspot mutation being confined to the malignant tumour areas (Table 1). A clonal NRAS c.181C > A p.-Gln61Lys variant (RefSeq Transcript NM_002524.5) was detected in low- and high-grade tumour areas as well as in two biopsies of skin affected by melanocytic naevi resulting in the diagnosis of neurocutaneous melanosis caused by postzygotic mosaicism of DICER1 syndrome and neurocutaneous melanosis caused by postzygotic mosaicism of DICER1 syndrome [8].

Key Points

- DICER1 mutant CNS sarcomas can arise in patients with neurocutaneous melanosis and DICER1 syndrome.
- These tumours may present with neural differentiation and a high degree of morphological and genetic intratumoural heterogeneity.
- Pleuropulmonary blastoma represents a relevant differential diagnosis in children with DICER1 mutant CNS sarcoma in a spinal location.
- MEK inhibition in addition to chemotherapy in a child with DICER1 mutant sarcoma resulted in improved response and complete remission.

The expanding histological spectrum of DICER1 mutant sarcomas argues for a precursor cell capable of multilineage differentiation regardless of the site. Neural crest cells migrate during early embryogenesis throughout the body and have a broad differentiation capacity ranging from neural tissue (melanocytes, neurons, Schwann cells) to mesenchymal tissue (chondrocytes, fibroblasts, and adipocytes; Figure 1A) [10]. In the case presented here, the patient developed a
FIGURE 1 Characteristics of a spinal tumour in a child with DICER1 syndrome and neurocutaneous melanosis. (A) Cerebellar hypoplasia and large arachnoid cyst and T1 hyperintense melanin deposits in pons and medulla oblongata (→). Formation of a tumour demonstrating various lineage differentiation (e.g., dysplastic neurons and neuropil, pseudo-meissnerian corpuscles – specialised schwannian cells, fibrovascular to immature chondroid matrix, adipocyte cell nests) with a malignant tumour component arising from the mesenchymal areas (primitive and sarcomatous differentiation; see Figure S2, online resource). (B) Synopsis: A multistep process of accumulating genetic events during embryogenesis in neural crest cell precursor cells leads to tumour formation and transformation in a DICER1 mutant sarcoma. Genetic intratumoural heterogeneity influences the degree of maturation and malignancy. Abbreviations: CNV, copy number alterations; NC, neural crest
highly heterogeneously differentiated neural-mesenchymal tumour with both constitutional DICER1 and mosaic NRAS mutation. In patients with neurocutaneous melanosis, the postzygotic NRAS mutation only affects a subpopulation of neural crest cells, but cannot be detected in the germline of the patient. We therefore deduce that the DICER1 mutant sarcoma with NRAS mutation in our patient arose from a neural crest cell by acquisition of a second mutation in DICER1 and chromosomal alterations (Figure 1B). As the tumour was epigenetically classified as primary intracranial sarcoma, DICER1-mutant and the methylation profile of a cancer cell strongly reflects the cell of origin [7], it is tempting to speculate that DICER1 mutant sarcomas in general are derived of neural crest cells which needs to be demonstrated in further studies. A synergistic effect in tumour formation of the germline DICER1 mutation and the somatic NRAS mutation may be assumed as NRAS mutations are found in approximately 10% of DICER1 mutant CNS sarcomas [1, 2].

It has been hypothesized that NRAS mutations in neurocutaneous melanosis occur before the differentiation of neural crest cells into the melanocytic lineage [11, 12]. A variety of non-melanotic tumours have been reported to arise in neurocutaneous melanosis patients, among them rhabdomyosarcomas and malignant peripheral nerve sheath tumours [12–14]. The level of differentiation and the environment of migrating neural crest cells at the time-point of acquisition of NRAS and/or DICER1 mutations during embryogenesis potentially influence the resulting phenotype and the variability in histological appearances of these tumours.

Here, we showed that DICER1 mutant CNS sarcoma may arise in spinal location and in the context of two co-occurring cancer predisposing conditions. Our temporal and spatially distinct analysis argues not only for a high morphological, but also genetic heterogeneity within DICER1 mutant CNS sarcomas, possibly relevant for future treatment strategies. Our study also provides a rationale to investigate DICER1 deficiency in neural crest cells in cell culture and mice.

**TABLE 1** Summary of genetic results of different specimens and tumour areas

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Tumour component</th>
<th>DICER1 (MAF)</th>
<th>DICER1 (MAF)</th>
<th>NRAS (MAF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>-</td>
<td>c.3007C &gt; T p.(Arg1003*) (heterozygous)</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Skin right arm</td>
<td>NA</td>
<td>NA</td>
<td>c.181C &gt; A p.Gln61Lys (20%)</td>
<td></td>
</tr>
<tr>
<td>Skin left leg</td>
<td>NA</td>
<td>NA</td>
<td>c.181C &gt; A p.Gln61Lys (7%)</td>
<td></td>
</tr>
<tr>
<td>Initial tumour</td>
<td>Malignant</td>
<td>p.(Glu1813Asp) (36.4%)</td>
<td>c.3007C &gt; T p.(Arg1003*) (40.3%)</td>
<td>c.181C &gt; A p.Gln61Lys (80.4%)</td>
</tr>
<tr>
<td></td>
<td>Low-grade</td>
<td>-</td>
<td>c.3007C &gt; T p.(Arg1003*) (43.7%)</td>
<td>c.181C &gt; A p.Gln61Lys (84.1%)</td>
</tr>
<tr>
<td>Residual tumour</td>
<td>Matured neural-mesenchymal</td>
<td>p.(Glu1813Asp) (2.8%)</td>
<td>c.3007C &gt; T p.(Arg1003*) (44%)</td>
<td>c.181C &gt; A p.Gln61Lys (31.3%)</td>
</tr>
</tbody>
</table>

Note: Next-generation sequencing (customised Nextera-DNA-Flex for Enrichment protocol, MiSeq Illumina) results from blood, two skin biopsies, malignant and low-grade component of the initial tumour and the residual tumour. The malignant tumour areas demonstrated biallelic inactivation of DICER1, whereas in other tissues, only the germline mutation was detected. The mosaic NRAS mutation was absent in the blood sample, but present in affected skin and both components of the tumour (MAFs in tumour samples may indicate a copy number neutral loss of heterozygosity of chromosome 1p, which cannot be detected by CNV analysis from methylation data). Variant annotation according to HGVS-nomenclature (Human Genome Variation Society), Transcripts DICER1 (NM_002524.5) and NRAS (NM_002524.5).

**ACKNOWLEDGEMENTS**

We gratefully thank Carola Geiler and Petra Matylewski for excellent technical support and Ulrich Schüller for helpful discussions. Open Access funding enabled and organized by Projekt DEAL.

**CONFLICT OF INTEREST**

The authors declare that they have no competing interests.

**ETHICS STATEMENT**

Written permission for publication was obtained from the parents of the child.

**AUTHOR CONTRIBUTIONS**

LS, WH and AK interpreted histopathological, immunohistochemical and molecular findings. DH, SH, KWP, IW and LS performed next-generation sequencing and assisted with sequencing interpretation. MN and AT interpreted radiological images. UT and VP provided neuro-surgical clinical care. RR, PH, KH and BZ provided neuro-oncology clinical care and assisted in data collection. LS prepared the figures and wrote the manuscript. All authors edited the manuscript and approved the final version.

**DATA AVAILABILITY STATEMENT**

Data are available upon reasonable request.

**ORCID**

Leonille Schweizer https://orcid.org/0000-0002-4649-2587

**REFERENCES**


SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Schweizer L, Hartmann W, Koch A, et al. Evidence of neural crest cell origin of a DICER1 mutant CNS sarcoma in a child with DICER1 syndrome and NRAS-mutant neurocutaneous melanosis. Neuropathol Appl Neurobiol. 2022;e12830. doi:10.1111/nan.12830